Thermo Fisher Scientific (NYSE: TMO) is reportedly in the preliminary stages of exploring the divestiture of certain diagnostic assets, including its microbiology unit. These assets are estimated to be worth around $4 billion and currently contribute over $1 billion in annual sales. The company is gauging interest from private equity firms; however, the potential sale remains uncertain at this point.
https://www.gurufocus.com/news/2925644/thermo-fisher-tmo-considers-4b-sale-of-diagnostic-assets
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.